Formulary Search

You are here : Home > Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Return to the search options.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Malignancy (Pamidronate disodium - Malignancy)

Records returned : 7 (on 29 May 2025 at 09:57:17). Return to search results for ' Malignancy '.

Show Icon and Status Keys Hide Icon and Status Keys

Icon Key

NFD1

Non formulary

NFD2

Not assessed for formulary status. Apply to APC / DTC before use.

Controlled drug. Prescribing and/or storage requirements may apply

Restrictions apply

Safety Alert

Unlicensed - no UK marketing license in place

Off-label use. Not licensed for this indication.

NHSE

Treatment commissioned by NHS England

CDF

Cancer Drugs Fund

ICB

Treatment commissioned by the ICB

BlueTeq form to be completed

NICE

Link to the NICE website

Low carbon device

Status Key

Red

Specialist ONLY drugs - treatment initiated and continued by specialist clinicians

Amber

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement

Green

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.

Green (see narrative)

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.

Non Formulary

Not recommended for use in any health setting across the Surrey Heartlands Integrated Care System

Blue

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.

See narrative

See narrative - may be applied in instances where a traffic light status has not yet been agreed but an entry to the formulary has been made to clarify interim arrangements.

Drug

Indication

Status

Restrictions/Comments

Formulary Status

Links

1. Pamidronate disodium

Drug:

Pamidronate disodium

Indication :

Malignancy

Status :

Red

Formulations :

Intravenous infusion

Restrictions / Comments:

Important

Used in

hypercalcaemia of malignancy
bone metastases
prevention of skeletal events

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

SPC

2. Ibandronic acid

Drug:

Ibandronic acid

Indication :

Malignancy

Status :

Blue

Formulations :

Tablets

Restrictions / Comments:

Important

50mg tablets for bone metastases in breast cancer. Specialist initiation and prescribing for at least 1 month before any request is made for primary care prescribing.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

SPC

6. Ibandronic acid

Drug:

Ibandronic acid

Indication :

Malignancy

Status :

Red

Formulations :

Intravenous infusion

Restrictions / Comments:

Important

Used in

hypercalcaemia of malignancy
bone metastases
prevention of skeletal events

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

SPC

3. Sodium clodronate

Drug:

Sodium clodronate

Indication :

Malignancy

Status :

Blue

Formulations :

Capsules

Restrictions / Comments:

Important

Hypercalcaemia of malignancy. Bone metastases. Prevention of skeletal events.
Initiation and stabilisation for a minimum of 3 months by specialist team before any request for primary care prescribing.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :